All, I think previouis post I had my lines slightly off which of course makes a difference I think we are on confluence support and beyond oversold/downtrend has to at least pop somewhat in my opiniong even if its $4-5. Looking for a bounce soon between weekly/daily change then getting 5-10 OTM options for calls or could do it now with maybe Aug/Sept.
NASDAQ:VRTX Possible Scenario: LONG Evidence: Price Action TP1: 219$ TP2: 225$ TP3: 247$ TP4: 270$ Call options, Strike 230$, 06/18/21 *This is my idea and could be wrong 100%
VRTX is close to previous support and lows of 2020. Looks like it is safe to buy.
Buy put spreads for April on this name. I think 180/165 put debit 4/19 would do well. XBI is under a lot of pressure, this company has nothing fresh right now, massive head and shoulders. Get it back in that safe channel
Fundamental & Chart Not for investment advice, personal notes only Chart: identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives. So far trend line remains intact, neckline of H&S shows no particular bearish...
VRTX has been inching closer to breaking out of its range state. With Biotech making new highs the stock should have flow tailwinds and any suppression of volatility in the market should be a positive.
- Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. - Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts - Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area...
Took two positions this morning in NASDAQ:VRTX and NASDAQ:MKTX .
VRTX up after exceeding earnings on JAN 30, finds support at 240. 5 day moving average is strong. Double inverted head and shoulders signals strong buy, possible breakout. Entry at 243, target price 252, stop loss 241.
Hi, today we are going to talk about Vertex Pharmaceuticals and its current landscape. Vertex Pharmaceuticals is poised to receive increasing attention from the market as relevant events are taking place after Proteostasis Therapeutics had unveiled "positive" data from a phase 2 clinical trial testing its triple-drug combination in patients with cystic fibrosis,...
Using a tight stop here with a wide target due to extended nature of this last impulse up and the fact that we're almost perfectly at the 1.618 extension of the last swing high -> swing low. You can tighten your stop to directly above the highest wick of this impulse as well if you want to increase the Reward:Risk Ratio. The other thing to watch is the...
$VRTX Overbought - beginning to retrace today closing well below yesterday's low, confirming bearish shooting star reversal candle from yesterday. Will be looking for additional 8-10% downside from today's close to the area of the 200d ema near term. (More downside possible depending on outcome of Feb ER) Target: $170-$175 range by mid February Also of note, in...
The slope of 30MM is positive, and the price is going up. If the price breaks de resistant, it will confirm phase 2.
Vertex has consolidating the price in a bullish wedge. A key resistence zone is at 178.57, a break out of such edge is interesting because it might pull up the price toward new high records. Stock is under the radar
$VRTX Vertex looking over-extended, reversing off the long term upper channel limit. Barring an earnings home run next week, expecting further price correction in the coming weeks and months. Medium term target: $163.50 Long term target: $153.50 (lower channel support) Earnings next week, 7/25 Note: Observation/opinion, not investment advice.